-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Apexigen (NASDAQ:APGN) Earns Buy Rating From Analysts at Roth Capital
Apexigen (NASDAQ:APGN) Earns Buy Rating From Analysts at Roth Capital
Roth Capital started coverage on shares of Apexigen (NASDAQ:APGN – Get Rating) in a research report report published on Tuesday morning, The Fly reports. The brokerage issued a buy rating and a $15.00 target price on the stock.
Other equities analysts also recently issued research reports about the company. EF Hutton Acquisition Co. I initiated coverage on Apexigen in a research note on Thursday, January 5th. They issued a buy rating and a $8.00 price objective on the stock. Brookline Capital Management reiterated a buy rating on shares of Apexigen in a research note on Monday, December 12th.
Get Apexigen alerts:Apexigen Trading Up 8.7 %
Apexigen stock opened at $1.99 on Tuesday. Apexigen has a 52 week low of $0.61 and a 52 week high of $31.35. The business's 50 day moving average price is $1.42.
Apexigen (NASDAQ:APGN – Get Rating) last posted its quarterly earnings data on Tuesday, November 15th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of $0.28 by ($0.69).Institutional Trading of Apexigen
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Decheng Capital Management III Cayman LLC purchased a new stake in Apexigen during the 3rd quarter worth about $5,115,000. Citadel Advisors LLC purchased a new stake in Apexigen during the 3rd quarter worth about $141,000. BlackRock Inc. purchased a new stake in Apexigen during the 3rd quarter worth about $577,000. Vanguard Group Inc. purchased a new stake in Apexigen during the 3rd quarter worth about $692,000. Finally, Two Sigma Investments LP purchased a new stake in Apexigen during the 3rd quarter worth about $38,000. 28.88% of the stock is currently owned by institutional investors.
Apexigen Company Profile
(Get Rating)
Apexigen Inc, a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells.
Further Reading
- Get a free copy of the StockNews.com research report on Apexigen (APGN)
- Is It Time To Get Aggressive With Defense Stocks?
- When Will Crane Holdings Take Flight?
- 3 Retail Stocks Ringing the Register in 2023
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
Receive News & Ratings for Apexigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apexigen and related companies with MarketBeat.com's FREE daily email newsletter.
Roth Capital started coverage on shares of Apexigen (NASDAQ:APGN – Get Rating) in a research report report published on Tuesday morning, The Fly reports. The brokerage issued a buy rating and a $15.00 target price on the stock.
罗斯资本开始报道的股票 Apexigen(纳斯达克股票代码:APGN — 获取评级) 在周二上午发布的研究报告中,The Fly报道。该经纪公司对该股发布了买入评级和15.00美元的目标价。
Other equities analysts also recently issued research reports about the company. EF Hutton Acquisition Co. I initiated coverage on Apexigen in a research note on Thursday, January 5th. They issued a buy rating and a $8.00 price objective on the stock. Brookline Capital Management reiterated a buy rating on shares of Apexigen in a research note on Monday, December 12th.
其他股票分析师最近也发布了有关该公司的研究报告。EF Hutton 收购公司我在1月5日星期四的一份研究报告中开始报道Apexigen。他们对该股发布了买入评级和8.00美元的目标价格。布鲁克林资本管理公司在12月12日星期一的一份研究报告中重申了对Apexigen股票的买入评级。
Apexigen Trading Up 8.7 %
Apexigen 交易价格上涨 8.7%
Apexigen stock opened at $1.99 on Tuesday. Apexigen has a 52 week low of $0.61 and a 52 week high of $31.35. The business's 50 day moving average price is $1.42.
Apexigen股票周二开盘价为1.99美元。Apexigen创下52周低点0.61美元,52周高点为31.35美元。该公司的50天移动平均价格为1.42美元。
Institutional Trading of Apexigen
Apexigen的机构交易
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Decheng Capital Management III Cayman LLC purchased a new stake in Apexigen during the 3rd quarter worth about $5,115,000. Citadel Advisors LLC purchased a new stake in Apexigen during the 3rd quarter worth about $141,000. BlackRock Inc. purchased a new stake in Apexigen during the 3rd quarter worth about $577,000. Vanguard Group Inc. purchased a new stake in Apexigen during the 3rd quarter worth about $692,000. Finally, Two Sigma Investments LP purchased a new stake in Apexigen during the 3rd quarter worth about $38,000. 28.88% of the stock is currently owned by institutional investors.
一些对冲基金和其他机构投资者最近对该股的头寸进行了调整。Decheng Capital Management III Caymant LLC在第三季度购买了Apexigen的新股份,价值约511.5万美元。Citadel Advisors LLC在第三季度购买了Apexigen的新股份,价值约14.1万美元。贝莱德公司在第三季度购买了Apexigen的新股份,价值约57.7万美元。Vanguard Group Inc.在第三季度购买了Apexigen的新股份,价值约69.2万美元。最后,Two Sigma Investments LP在第三季度购买了Apexigen的新股份,价值约38,000美元。该股中有28.88%目前由机构投资者持有。
Apexigen Company Profile
Apexigen 公司简介
(Get Rating)
(获取评分)
Apexigen Inc, a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells.
Apexigen Inc是一家临床阶段的生物制药公司,它发现并开发了用于肿瘤的抗体疗法。它开发了一系列候选产品,包括 APX005M,一种人源化激动剂抗体,正在二期临床开发中,用于治疗实体瘤,例如黑色素瘤、食管和胃食管交界处、肉瘤以及与免疫疗法、化疗、放射疗法和癌症疫苗联合使用的直肠癌和卵巢癌;以及 APX601,一种用于治疗多种肿瘤适应症的 I/II 期临床试验还有 APX801,一种用于激活自然杀伤细胞进行杀伤的 NK 细胞参与者肿瘤细胞的。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Apexigen (APGN)
- Is It Time To Get Aggressive With Defense Stocks?
- When Will Crane Holdings Take Flight?
- 3 Retail Stocks Ringing the Register in 2023
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- 免费获取 StockNews.com 关于 Apexigen(APGN)的研究报告的副本
- 是时候对国防股采取积极行动了吗?
- Crane Holdings 什么时候起飞?
- 2023 年有 3 只零售股大放异彩了
- 高通得到了分析师的提振,但现在是买入的时候了吗?
- EvGo 股票备受冲击,可以顺应电动汽车的采用浪潮
Receive News & Ratings for Apexigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apexigen and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Apexigen Daily 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Apexigen及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧